Targeting novel signaling pathways for resistant acute myeloid leukemia

Kathleen M. Sakamoto; Steven Grant; Diana Saleiro; John D. Crispino; Nobuko Hijiya; Francis Giles; Leonidas Platanias; Elizabeth A. Eklund

doi:10.1016/j.ymgme.2014.11.017

Targeting novel signaling pathways for resistant acute myeloid leukemia

Kathleen M. Sakamoto^*, Steven Grant, Diana Saleiro, John D. Crispino, Nobuko Hijiya, Francis Giles, Leonidas Platanias, Elizabeth A. Eklund

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

60 Scopus citations

Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.

Original language	English (US)
Pages (from-to)	397-402
Number of pages	6
Journal	Molecular Genetics and Metabolism
Volume	114
Issue number	3
DOIs	https://doi.org/10.1016/j.ymgme.2014.11.017
State	Published - Mar 1 2015

Funding

K.M.S. is supported by the NIH ( R01 HL75826 , R01 GM087305 ), Leukemia and Lymphoma Society of America Screen to Lead Program, Hyundai Hope on Wheels , Stanford SPARK/Child Health Research Institute , S.G. is supported by the NIH ( CA142509 , CA167708 ) and Leukemia and Lymphoma Society of America (# 6472-15 ). L.C.P. is supported by grants from the NIH ( R01 CA77816 , CA155566 , CA161196 and CA121192 ) and Department of Veterans Affairs ( I01CX000916 ). J.C. is supported by the Samuel Waxman Cancer Research Foundation and NIH ( R01 CA101774 ). E.A.E. is supported by NIH ( R01 CA174205 , DK098812 ) and VA Merit Review .

Keywords

Acute myeloid leukemia
Novel therapies
Resistance
Signaling pathways

ASJC Scopus subject areas

Genetics
Endocrinology
Molecular Biology
Biochemistry
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ymgme.2014.11.017

Cite this

@article{f694a2746697432197eb4bc8878a9ec6,

title = "Targeting novel signaling pathways for resistant acute myeloid leukemia",

abstract = "Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.",

keywords = "Acute myeloid leukemia, Novel therapies, Resistance, Signaling pathways",

author = "Sakamoto, {Kathleen M.} and Steven Grant and Diana Saleiro and Crispino, {John D.} and Nobuko Hijiya and Francis Giles and Leonidas Platanias and Eklund, {Elizabeth A.}",

note = "Funding Information: K.M.S. is supported by the NIH ( R01 HL75826 , R01 GM087305 ), Leukemia and Lymphoma Society of America Screen to Lead Program, Hyundai Hope on Wheels , Stanford SPARK/Child Health Research Institute , S.G. is supported by the NIH ( CA142509 , CA167708 ) and Leukemia and Lymphoma Society of America (# 6472-15 ). L.C.P. is supported by grants from the NIH ( R01 CA77816 , CA155566 , CA161196 and CA121192 ) and Department of Veterans Affairs ( I01CX000916 ). J.C. is supported by the Samuel Waxman Cancer Research Foundation and NIH ( R01 CA101774 ). E.A.E. is supported by NIH ( R01 CA174205 , DK098812 ) and VA Merit Review . Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/j.ymgme.2014.11.017",

language = "English (US)",

volume = "114",

pages = "397--402",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Targeting novel signaling pathways for resistant acute myeloid leukemia

AU - Sakamoto, Kathleen M.

AU - Grant, Steven

AU - Saleiro, Diana

AU - Crispino, John D.

AU - Hijiya, Nobuko

AU - Giles, Francis

AU - Platanias, Leonidas

AU - Eklund, Elizabeth A.

N1 - Funding Information: K.M.S. is supported by the NIH ( R01 HL75826 , R01 GM087305 ), Leukemia and Lymphoma Society of America Screen to Lead Program, Hyundai Hope on Wheels , Stanford SPARK/Child Health Research Institute , S.G. is supported by the NIH ( CA142509 , CA167708 ) and Leukemia and Lymphoma Society of America (# 6472-15 ). L.C.P. is supported by grants from the NIH ( R01 CA77816 , CA155566 , CA161196 and CA121192 ) and Department of Veterans Affairs ( I01CX000916 ). J.C. is supported by the Samuel Waxman Cancer Research Foundation and NIH ( R01 CA101774 ). E.A.E. is supported by NIH ( R01 CA174205 , DK098812 ) and VA Merit Review . Publisher Copyright: © 2014 Elsevier Inc.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.

AB - Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.

KW - Acute myeloid leukemia

KW - Novel therapies

KW - Resistance

KW - Signaling pathways

UR - http://www.scopus.com/inward/record.url?scp=84924122265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924122265&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2014.11.017

DO - 10.1016/j.ymgme.2014.11.017

M3 - Review article

C2 - 25533111

AN - SCOPUS:84924122265

SN - 1096-7192

VL - 114

SP - 397

EP - 402

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 3

ER -

Targeting novel signaling pathways for resistant acute myeloid leukemia

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this